The MAPKAPK2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the MAPKAPK2 gene has been disrupted using CRISPR/Cas9-mediated genome editing. This product consists of a heterogeneous pool of Raji B lymphocyte cells carrying diverse loss-of-function mutations at the MAPKAPK2 locus, thereby avoiding the artifacts associated with clonal selection. As a polyclonal knockout model, it provides a physiologically relevant system for studying the collective functional consequences of MAPKAPK2 deficiency in a lymphoid cellular context.
The parental Raji cell line is an Epstein-Barr virus-positive lymphoblastoid line established from a Burkitt lymphoma patient. These B lymphocytes exhibit epithelial-like morphology and are extensively utilized in immunological and oncological research for probing B-cell signaling, lymphomagenesis, and tumor immunology. Their stable growth characteristics and well-defined genetic background make them a highly tractable host for gene-editing applications and for dissecting kinase functions in hematological malignancies.
MAPKAPK2 (MK2) is a serine/threonine kinase that operates as a major downstream effector of the p38 MAPK signaling pathway. Following activation by p38 MAPK (MAPK14) in response to stress stimuli (osmotic shock, UV) or pro-inflammatory cytokines (TNF-alpha, IL-1beta), MAPKAPK2 directly phosphorylates tristetraprolin (TTP/ZFP36), an mRNA-destabilizing factor, inhibiting its activity. This leads to stabilization of AU-rich element-containing mRNAs, including those encoding TNF-alpha, IL-6, and COX-2, thereby enhancing cytokine production. MAPKAPK2 also phosphorylates HSP27, facilitating actin cytoskeleton reorganization and promoting cell migration. The kinase interacts with multiple upstream regulators (Akt, ERK, RSK) that fine-tune its activity, placing MAPKAPK2 at a convergence point for post-transcriptional gene regulation and cytoskeletal remodeling.
In the Raji B lymphocyte lymphoma context, disruption of MAPKAPK2 provides an advanced model to elucidate the p38-MK2 axis in inflammation-driven B-cell malignancies. Raji cells exhibit constitutive activation of NF-??B and stress kinase pathways, closely mirroring the signaling environment of many lymphomas. Consequently, this polyclonal knockout system permits the investigation of how MAPKAPK2 controls pro-inflammatory gene expression and actin dynamics, which are processes implicated in lymphoma progression and immune evasion. The model is especially suited to explore therapeutic interventions targeting the p38-MAPKAPK2 module.
Researchers can apply these cells in a broad array of experimental settings. Western blotting for phosphorylated MK2 and HSP27 assesses kinase activity, while ELISA quantifies cytokine secretion (e.g., TNF-alpha, IL-6). RT-qPCR monitors the stability of ARE-containing transcripts, and immunofluorescence visualizes HSP27 relocalization during actin remodeling. Migration assays and drug sensitivity profiling further support studies on cell motility and anti-inflammatory drug screening. For additional product information and technical support, please contact Ascent Research.
